Aptevo Therapeutics (APVO) and Bioblast Pharma (ORPN) Head-To-Head Contrast

Aptevo Therapeutics (NASDAQ: APVO) and Bioblast Pharma (NASDAQ:ORPN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Insider & Institutional Ownership

33.2% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 1.5% of Bioblast Pharma shares are held by institutional investors. 15.6% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aptevo Therapeutics and Bioblast Pharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics 0 0 1 0 3.00
Bioblast Pharma 0 0 0 0 N/A

Aptevo Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 82.37%. Bioblast Pharma has a consensus price target of $3.15, suggesting a potential upside of 10.92%. Given Aptevo Therapeutics’ higher probable upside, analysts plainly believe Aptevo Therapeutics is more favorable than Bioblast Pharma.

Valuation and Earnings

This table compares Aptevo Therapeutics and Bioblast Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aptevo Therapeutics $36.43 million 1.94 -$112.41 million N/A N/A
Bioblast Pharma N/A N/A -$16.02 million ($2.57) -1.11

Bioblast Pharma has lower revenue, but higher earnings than Aptevo Therapeutics.

Risk & Volatility

Aptevo Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Bioblast Pharma has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.

Profitability

This table compares Aptevo Therapeutics and Bioblast Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aptevo Therapeutics 5.40% -28.03% -17.46%
Bioblast Pharma N/A -144.37% -119.42%

Summary

Aptevo Therapeutics beats Bioblast Pharma on 8 of the 10 factors compared between the two stocks.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).

Bioblast Pharma Company Profile

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich’s ataxia) and BBrm-02. The Company’s product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply